Aggressive fibromatosis
Rare, locally invasive tumors with unpredictable clinical behavior.
Aggressive fibromatosis, also known as desmoid tumor, is a rare condition characterized by locally aggressive, invasive growths arising from fibroblasts. Though related to sarcoma, these tumors do not metastasize, but they can cause pain, life-threatening problems, or rarely death by invading soft tissues or compressing vital organs. The condition is notable for its variable and unpredictable clinical course, with a tendency to recur even after complete resection.
- field
- Oncology, Pathology
- known_for
- Locally aggressive fibroblastic tumors without metastatic potential
- common_in
- Women in their thirties
- associated_with
- Familial adenomatous polyposis (FAP), Gardner's syndrome
- recurrence_risk
- High, especially after prior surgery
Lore & Background
Desmoid tumors arise from fibroblasts, cells that provide structural support and play a critical role in wound healing. They can occur anywhere in the body and are classified as extra-abdominal, abdominal wall, or intra-abdominal, with the latter more common in patients with familial adenomatous polyposis (FAP). Most cases are sporadic, with 85% involving a CTNNB1 mutation; the 45F mutation is associated with a high risk of recurrence. APC mutations are very rare in sporadic cases (less than 5%) but are commonly found in FAP-associated desmoids, where they account for 10–15% of cases. The disease has a hormonal link, with a tendency to occur during and after pregnancy and after exposure to higher estrogen levels. Trauma and surgery are also risk factors.
Reader's Guide
Aggressive fibromatosis is significant because it represents a rare, non-metastasizing but locally aggressive tumor that can be debilitating and, in some cases, life-threatening. Its unpredictable course—ranging from spontaneous resolution to rapid progression—poses challenges for management. Historically, surgery was the standard treatment, but since the early 2000s, conservative approaches such as watchful waiting have become common due to high recurrence rates and the infiltrative nature of the tumors. In 2020, the World Health Organization reclassified desmoid-type fibromatosis as an intermediate (locally aggressive) fibroblastic tumor. The first FDA-approved medication, nirogacestat, arrived in November 2023, and other targeted therapies are under development. The condition's association with Wnt signaling pathway alterations has driven research into new treatments, including gamma secretase inhibitors and beta-catenin inhibitors. Diagnosis remains challenging, with 30–40% of cases potentially misdiagnosed, and a biopsy is definitive. The legacy of aggressive fibromatosis lies in its shift from surgical to multimodal management and its role in advancing understanding of fibroblastic tumors.
Did You Know?
- Desmoid tumors cannot metastasize but can be multifocal, with several tumors in the same body part.
- Approximately 10% of individuals with Gardner's syndrome have desmoid tumors.
- Two-thirds of patients with desmoid tumors in one study had a history of prior abdominal surgery.
- Desmoid tumors of the breast can mimic breast cancer on physical examination and imaging.
More in Rare diseases 1-24
Spotted an error? Know more?
This is a living reference — every entry is fact-audited, and reader corrections feed straight into our audit queue. Suggest an edit · See this site's audit record